Two young boys from Syracuse need a life saving bone marrow transplant. For one of them especially, the time is ticking.

WASHINGTON — The investigational anti-CD40 ligand agent dapirolizumab pegol (DZP) outperformed placebo in improving disease activity and reducing high-dose corticosteroid use in patients with systemic ...

Frankfurt, Germany - Soluble CD40 ligand can be used to identify ACS patients at highest risk for cardiac events and those who will receive most benefit from the GP IIb/IIIa blocker abciximab, a new ...

For years, a Syracuse family has been searching for something most people never have to think about... a match.Two brothers, ...

Treatment with the investigational CD40 ligand inhibitor frexalimab significantly reduced new MRI lesions in relapsing multiple sclerosis (MS) by week 24, according to data presented at the joint ...

BOSTON--(BUSINESS WIRE)--Boston Immune Technologies and Therapeutics, Inc. (BITT), a clinical-stage biotechnology company developing novel tumor necrosis factor superfamily receptor (TNFSR) antagonist ...

Eledon Pharmaceuticals announced that their investigational anti-CD40L antibody, tegoprubart, was successfully used in the immunosuppression regimen for a patient who recently received a kidney ...

Eledon Pharmaceuticals' Tegoprubart, a second-gen anti-CD40L antibody, shows promise in preventing organ rejection without thromboembolic risks, addressing unmet needs in kidney and islet cell ...

BARCELONA -- A novel antibody-based drug targeting the CD40 ligand helped close to half of patients with treatment-refractory systemic lupus erythematosus (SLE) get symptoms under control, according ...

Over the past 20 years, a class of anticancer drugs called CD40 agonist antibodies has shown great promise but also induced great disappointment. While such drugs have been effective at activating the ...